MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
138 M |
Market Cap[1] |
$ 1.15 B |
EBITDA (LTM) |
$ -233 M |
P/E (LTM) |
-4.859589 |
P/S (LTM) |
204.404278 |
EPS (LTM) |
-2.92 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Oncolytics Biotech
ONCY
|
$ 0.45 | 5.32 % | $ 43.1 M | Nasdaq Global Select Market |  Canada |
 |
ORIC Pharmaceuticals
ORIC
|
$ 8.47 | -9.37 % | $ 744 M | Nasdaq Global Select Market | USA |
 |
Oramed Pharmaceuticals
ORMP
|
$ 3.91 | -5.45 % | $ 162 M | Nasdaq Global Select Market |  Israel |
 |
Puma Biotechnology
PBYI
|
$ 9.88 | -7.58 % | $ 494 M | Nasdaq Global Select Market | USA |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.17 | -10.0 % | $ 54.3 M | Nasdaq Capital Market | USA |
 |
Pfizer
PFE
|
$ 30.03 | -2.47 % | $ 171 B | NYSE,SPB | USA |
 |
Pharming Group N.V.
PHAR
|
$ 12.53 | 0.56 % | $ 8.63 B | Nasdaq Global Select Market |  Niderland |
 |
Phathom Pharmaceuticals
PHAT
|
$ 5.07 | -10.83 % | $ 370 M | Nasdaq Global Select Market,SPB | USA |
 |
Pliant Therapeutics
PLRX
|
$ 0.81 | -4.85 % | $ 49.7 M | Nasdaq Global Select Market | USA |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Protalix BioTherapeutics
PLX
|
$ 2.51 | -6.69 % | $ 197 M | NYSE American | Israel |
 |
PMV Pharmaceuticals
PMVP
|
$ 1.28 | -3.4 % | $ 67.3 M | Nasdaq Global Select Market | USA |
 |
PTC Therapeutics
PTCT
|
$ 65.61 | -4.87 % | $ 5.22 B | Nasdaq Global Select Market,SPB | USA |
 |
BioVie
BIVI
|
$ 1.21 | -9.7 % | $ 1.79 M | Nasdaq Capital Market | USA |
 |
Protagonist Therapeutics
PTGX
|
$ 135.02 | -6.05 % | $ 8.58 B | Nasdaq Global Select Market | USA |
 |
Pulmatrix
PULM
|
$ 1.46 | -4.28 % | $ 5.33 B | Nasdaq Global Select Market | USA |
 |
Sage Therapeutics
SAGE
|
- | - | $ 527 M | Nasdaq Global Select Market,SPB | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
- | - | $ 1.62 B | NYSE | Israel |
 |
Rocket Pharmaceuticals
RCKT
|
$ 2.44 | -6.7 % | $ 271 M | Nasdaq Global Select Market | USA |
 |
Arcus Biosciences
RCUS
|
$ 17.96 | -6.92 % | $ 1.93 B | NYSE,SPB | USA |
 |
Cabaletta Bio
CABA
|
$ 1.26 | -10.92 % | $ 127 M | Nasdaq Global Select Market | USA |
 |
Forma Therapeutics Holdings
FMTX
|
- | - | $ 958 M | Nasdaq Global Market | USA |
 |
Relay Therapeutics
RLAY
|
$ 17.0 | -5.74 % | $ 2.92 B | Nasdaq Global Market | USA |
 |
Blueprint Medicines Corporation
BPMC
|
- | - | $ 8.14 B | Nasdaq Global Select Market,SPB | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
- | - | $ 26.6 B | Nasdaq Global Select Market |  Irlanda |
 |
Paratek Pharmaceuticals
PRTK
|
- | - | $ 121 M | Nasdaq Global Market | USA |
 |
Royalty Pharma plc
RPRX
|
$ 67.55 | -0.02 % | $ 29 B | Nasdaq Global Select Market | USA |
 |
Revolution Medicines
RVMD
|
$ 177.88 | -10.93 % | $ 33.8 B | Nasdaq Global Select Market | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
- | -14.27 % | $ 1.7 M | Nasdaq Global Market |  Singapore |
 |
Rhythm Pharmaceuticals
RYTM
|
$ 105.13 | -5.01 % | $ 6.83 B | Nasdaq Global Market,SPB | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
$ 0.42 | 0.62 % | $ 5.18 B | Nasdaq Global Market | Israel |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Unity Biotechnology
UBX
|
- | -33.41 % | $ 3.37 M | Nasdaq Global Select Market | USA |
 |
iTeos Therapeutics
ITOS
|
- | - | $ 411 M | Nasdaq Global Market | USA |
 |
Fulcrum Therapeutics
FULC
|
$ 3.69 | -2.25 % | $ 234 M | Nasdaq Global Market | USA |
 |
Achieve Life Sciences
ACHV
|
$ 6.39 | -8.42 % | $ 279 M | Nasdaq Capital Market | USA |
 |
Seelos Therapeutics
SEEL
|
- | -47.76 % | $ 6.27 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Sol-Gel Technologies Ltd.
SLGL
|
$ 63.01 | -4.53 % | $ 176 M | Nasdaq Global Select Market | Israel |
 |
SELLAS Life Sciences Group
SLS
|
$ 7.84 | -14.28 % | $ 855 M | Nasdaq Capital Market | USA |
 |
Syndax Pharmaceuticals
SNDX
|
$ 9.34 | -10.67 % | $ 809 M | Nasdaq Global Select Market | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
$ 4.63 | 21.05 % | $ 20 M | Nasdaq Capital Market | Israel |
 |
Spero Therapeutics
SPRO
|
$ 1.02 | -4.82 % | $ 57.1 M | Nasdaq Global Select Market | USA |
 |
Kiromic BioPharma
KRBP
|
- | 6.61 % | $ 3.08 M | Nasdaq Global Select Market | USA |
 |
CNS Pharmaceuticals
CNSP
|
$ 4.01 | -7.6 % | $ 1.78 M | Nasdaq Capital Market | USA |
 |
Geron Corporation
GERN
|
$ 0.95 | -11.87 % | $ 633 M | Nasdaq Global Select Market | USA |
 |
Stoke Therapeutics
STOK
|
$ 26.09 | -4.95 % | $ 1.55 B | Nasdaq Global Select Market,SPB | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Sutro Biopharma
STRO
|
$ 9.16 | -7.8 % | $ 77.8 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.